Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

Abstract 1.  It has previously been demonstrated that metabolism of drugs via a single enzymatic pathway, particularly CYP3A4, is associated with increased risk for drug-drug interactions (DDI). Quantitative experimental systems as well as integrated prediction models to assess such risk during the...

Full description

Saved in:
Bibliographic Details
Published in:Xenobiotica 2014-01, Vol.44 (1), p.17-27
Main Authors: Desbans, C., Hilgendorf, C., Lutz, M., Bachellier, P., Zacharias, T., Weber, J. C., Dolgos, H., Richert, L., Ungell, A.-L.
Format: Article
Language:English
Subjects:
Chromatography, High Pressure Liquid
Cryopreservation - methods
CYP450 inhibition
Cytochrome P-450 CYP3A - metabolism
DDI risk
Drug Interactions - physiology
Hepatocytes - metabolism
hepatocytes suspension
Humans
ketoconazole
Mass Spectrometry
Metabolic Networks and Pathways - physiology
Models, Biological
Pharmaceutical Preparations - metabolism
preclinical
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 1.  It has previously been demonstrated that metabolism of drugs via a single enzymatic pathway, particularly CYP3A4, is associated with increased risk for drug-drug interactions (DDI). Quantitative experimental systems as well as integrated prediction models to assess such risk during the preclinical phase are highly warranted. 2.  The present study was designed to systematically investigate the performance of human cryopreserved hepatocytes in suspension to predict fraction metabolized via CYP3A (fmCYP3A) by assessing the ketoconazole sensitive intrinsic clearance (CLint) for five prototypical CYP3A substrates with varying degree of CYP3A dependent CLint in twelve individual hepatocyte batches. 3.  We demonstrate that in contrast to well predicted mean hepatic metabolic clearance (CLH) and mean fmCYP3A data, the variability in CYP3A contribution for compounds having multiple metabolic pathways cannot be predicted from inhibition experiments using ketoconazole as inhibitor. Instead, data in the present paper indicate that the variability is larger after inhibition of CYP3A for compounds having multiple metabolic pathways. 4.  It is therefore recommended to estimate the average CLint and fmCYP3A for a given test compound in a series (n = 10) of individual human hepatocyte batches.
ISSN:0049-8254
1366-5928
1366-5928
DOI:10.3109/00498254.2013.809617